← Back to Search

Amino Acid Supplement

Amino Acid Supplement for Insulin-Like Growth Factor I (IGF-I)

Phase 2
Waitlist Available
Led By David Crowley, MD
Research Sponsored by ZandA Technologies, llc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) and 91 days

Summary

This trial is testing a steroid pill to see if it can increase levels of a growth factor in the blood. The study focuses on adults aged 35-75 because they often have lower levels of this growth factor. Researchers will also check if the pill is safe and well-tolerated.

Eligible Conditions
  • Insulin-Like Growth Factor I (IGF-I)
  • Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) and 91 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1) and 91 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Somatomedins
The difference in serum IGF-1 concentrations from baseline up to 60 days of supplementation between Amino Acid Supplement (AAS) compared to placebo.
Somatomedins
Secondary study objectives
Amino Acids
Amino Acids

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Amino Acid SupplementExperimental Treatment1 Intervention
Participants will be instructed to take four (4) capsules of Amino Acid Supplement with a full glass of water daily for up to 90 days, starting on day 1. No substance other than water (i.e., food, drink other than water, and/or medication, supplement, vitamin, and/or mineral) can be consumed two hours before or after taking the Investigational Product (IP). The IP must be consistently consumed immediately before nighttime sleep throughout the study. If a dose is missed participants are instructed to record the missed dose in their study journal. Missed doses will not be taken at a later time or date. If any substance other than water is consumed two hours before or after taking the IP, that IP use will be counted as a missed dose. Participants will be advised not to exceed four (4) capsules daily.
Group II: PlaceboPlacebo Group1 Intervention
Participants will be instructed to take four (4) capsules of Placebo with a full glass of water daily for up to 90 days, starting on day 1. No substance other than water (i.e., food, drink other than water, and/or medication, supplement, vitamin, and/or mineral) can be consumed two hours before or after taking the placebo. The placebo must be consistently consumed immediately before nighttime sleep throughout the study. If a dose is missed participants are instructed to record the missed dose in their study journal. Missed doses will not be taken at a later time or date. If any substance other than water is consumed two hours before or after taking the placebo, that placebo use will be counted as a missed dose. Participants will be advised not to exceed four (4) capsules daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amino Acid Supplement
2022
Completed Phase 2
~120

Find a Location

Who is running the clinical trial?

KGK Science Inc.Industry Sponsor
78 Previous Clinical Trials
6,040 Total Patients Enrolled
ZandA Technologies, llcLead Sponsor
David Crowley, MDPrincipal InvestigatorKGK Science Inc.
35 Previous Clinical Trials
2,633 Total Patients Enrolled

Media Library

Amino Acid Supplement (Amino Acid Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT05599282 — Phase 2
Insulin-Like Growth Factor I (IGF-I) Research Study Groups: Amino Acid Supplement, Placebo
Insulin-Like Growth Factor I (IGF-I) Clinical Trial 2023: Amino Acid Supplement Highlights & Side Effects. Trial Name: NCT05599282 — Phase 2
Amino Acid Supplement (Amino Acid Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05599282 — Phase 2
~40 spots leftby Nov 2025